

ADVANCING IMMUNO-ONCOLOGY SCIENCE THROUGH COLLABORATION

The Immuno-Oncology Integrated Community Oncology Network (IO-ICON) is an innovative collaboration of health care professionals, scientists and industry. Established by cancer experts and Bristol-Myers Squibb, IO-ICON is working to help provide patients with access to cutting-edge Immuno-Oncology research in their own communities.

Evolving and Enhancing the Status Quo for the Over 80% of People With Cancer Who Receive Treatment in Their Own Communities

Network goals are to be:



VISIONARY: seeing beyond the status quo to evolve and enhance community research



COLLABORATIVE: working together to advance research with urgency



DATA FOCUSED: gathering data to increase understanding and integrate knowledge into future research



OPERATIONALLY EFFICIENT:

by simplifying the process and providing education



PATIENT FOCUSED: responding to changing patient needs

Increasing patient access to local clinical trials



110+ members across 8 community networks

Over **2,900 sites** in 29 states





2 million+ patients reached annually

Connecting Community Oncology Networks to Advance the Science

IO-ICON brings together insights from:



Community Oncologists



Pharmacists



Nurses



Clinical Staff and Educators



Immunologists



Molecular Profiling and Bioinformatics Specialists



Bristol-Myers Squibb R&D and Medical Representatives

Driving Clinical Research Through Data Generation

IO-ICON generates data via clinical trials and real-world analyses.

38+ Phase I-4 studies to date, enrolling
4,500+ patients





Tracking medicines in the "real world" to:

- Understand outcomes
- Better manage adverse events
- Uncover patient characteristics to inform treatment decisions



IO-ICON and Bristol-Myers Squibb share a common goal to advance cancer research, with the hope of improving patient outcomes and understand there is more to be done.

